Those slides were updated on March 28th. One u

Those slides were updated on March 28th.

One update to the website (at least that I didn't previously notice) is the addition of the COVID-19 indication under the Pipeline tab.

https://www.cytodyn.com/pipeline/covid-19

Here is a couple interesting excerpts from this page:

Potential Benefits of Leronlimab in COVID-19

Recent laboratory data for patients treated with leronlimab for COVID-19 infection has shown increases in the profoundly decreased CD8 T-lymphocyte percentages by Day 3, normalization of CD4/CD8 ratios, and resolving cytokine production including reduced IL-6 correlating with patient improvement. The current data suggests a trend toward the restoration of immune function by day 7. Restoration of the immune function is critical in COVID-19 patients to prevent opportunistic infections.

Future Research for Leronlimab in Immune Dysfunction

The mechanism of action of leronlimab in quieting the cytokine storm and restoration of immune function is an important mechanism that has applicability across multiple disease processes. CytoDyn will be exploring these opportunities to help patients and expand the pipeline of opportunities for leronlimab.

It doesn't yet have a link to the clinical trial, but I expect this to be updated as soon as these trials are posted on the clinicaltrials.gov website.

Please do your own due diligence. All my posts and comments are not to be considered investment advice.